gastroesophageal reflux disease

Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers.

PF 03716556 (PF-3716556) , an effective and specific P-CAB (potassium-competitive acid blocker), is utilized for the treatment of gastroesophageal reflux disease.

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.

Metoclopramide (5-Chloro-2-methoxyprocainamide) is a dopamine D2 antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In various countries, metoclopramide is the antiemetic drug of choice in pregnant women. Findings provide reassurance regarding the safety of metoclopramide for the fetus when the drug is given to women to relieve nausea and vomiting during pregnancy. Evidence also supports its use for gastroparesis (poor stomach emptying) and gastroesophageal reflux disease. It appears to bind to dopamine D2 receptors where it is a receptor antagonist, and is also a mixed 5-HT3 receptor antagonist 5-HT4 receptor agonist.

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Esomeprazole Magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a proton pump inhibitor indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases

Lavoltidine (Loxtidine) is a potent and selective H2 receptor antagonist, orally active and irreversible, that inhibits gastric acid secretion and is used in the treatment of gastroesophageal reflux disease.

Lafutidine (FRG-8813) is a newly developed histamine H2-receptor antagonist that inhibits gastric acid secretion.

Itopride HCl is an AChE inhibitor and dopamine D2 receptor antagonist. It inhibits lower esophageal sphincter relaxation. It also used to treat functional dyspepsia and gastroesophageal reflux disease

Nizatidine (Acinon) is a competitive and reversible histamine H2-receptor antagonist with antacid activity.

Pumosetrag Hydrochloride is an orally available 5-HT3 partial agonist. It is developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

Revexepride is a highly selective agonist of the 5-HT4 receptor and a potential inducer of CYP3A4 enzyme. Revexepride is used for the treatment of gastroesophageal reflux disease.

Ilaprazole (IY-81149) is a proton pump inhibitor used in the treatment of dyspepsia gastroesophageal reflux disease (GORD GERD) and duodenal ulcer. Studies also showed that Ilaprazole significantly prevented the development of reflux oesophagitis.

Ranitidine-S-oxide is a metabolite of Ranitidine. It is commonly used in the treatment of peptic ulcer disease, Zollinger–Ellison syndrome，and gastroesophageal reflux disease.

Lansoprazole sodium (Lansoprazole (sodium)) is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease.

Azeloprazole, a proton pump inhibitor, is used potentially for the treatment of gastroesophageal reflux disease (GERD).

Arbaclofen placarbil( XP19986) is a GABA(B) receptor agonist.Arbaclofen Placarbil is a novel R-baclofen prodrug with improved absorption, distribution, metabolism, and elimination properties compared to R-baclofen. And it can reduce postprandial reflux in

Famotine Hydrochloride is a histamine H2 receptor antagonist that suppresses acid production in the stomach and commonly treats peptic ulcer disease and gastroesophageal reflux disease.

Mitemcinal fumarate is a erythromycin derivative that is used to treat gastroesophageal reflux disease.

Esomeprazole magnesium salt is a potent and orally active proton pump inhibitor that effectively reduces acid secretion in gastric parietal cells by inhibiting the H+, K+-ATPase. This compound has shown promise for the research and treatment of symptomatic gastroesophageal reflux disease [1][2][3].

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively functions as a potassium-competitive acid blocker (P-CAB) with potent antisecretory properties. It significantly inhibits H+,K+-ATPase activity in porcine gastric microsomes, displaying an IC50 of 19 nM at pH 6.5. Developed primarily for researching acid-related conditions such as gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also aids in the eradication of Helicobacter pylori [1] [2] [3].

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is an effective and orally active proton pump inhibitor that inhibits H+, K+-ATPase enzyme in gastric parietal cells, reducing acid secretion. It is a promising compound for investigating symptomatic gastroesophageal reflux disease [1] [2] [3].

Esomeprazole hemistrontium, also known as (S)-Omeprazole, is a potent and orally active proton pump inhibitor that effectively reduces acid secretion by inhibiting the H+, K+-ATPase in gastric parietal cells. This compound exhibits promising potential for research in symptomatic gastroesophageal reflux disease [1] [2] [3].